Dual orexin receptor antagonists, such as suvorexant, have shown promise in reducing amyloid‐β and tau accumulation in Alzheimer's disease, as well as ameliorating sleep alterations in Huntington's and ALS models. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.